2019-001316-38: A clinical trial on an individualized treatment strategy for patients with metastatic non-clear cell kidney cancer Et lægemiddelforsøg af en individualiseret behandlingsstrategi til patienter med undertypen non-clear celle nyrekræft, som har spredt sig |
|
|
| Not yet recruiting | 2 | 30 | Europe | Capsule, hard, Film-coated tablet, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Tafinlar, Tarceva, Keytruda, Mekinist, Alecensa, Lynparza, Kadcyla, Cabometyx, Xalkori, Ibrance, Tagrisso, Glivec, Sutent, Opdivo | Department of Oncology, Herlev University Hospital, Region Hovedstaden, Roche Denmark | Patients with metastatic non-clear cell or 100% sarcomatoid renal cell carcinoma referred for first line treatment at the Department of Oncology, Herlev University Hospital Patienter med metastatisk non-clear cell eller 100% sarkomatoid nyrekræft, som henvises med henblik på første linje behandling på onkologisk afdeling, Herlev Hospital, Patients with metastatic kidney cancer with the subtype non-clear cell or 100% sarcomatoid referred for first line treatment at the Department of Oncology, Herlev University Hospital Patienter med undertypen non-clear cell eller 100% sarkomatoid nyrekræft, som har spredt sig og henvises for at påbegynde den første medicinske kræftbehandling på onkologisk afdeling, Herlev Hospital, Diseases [C] - Cancer [C04] | | | | |
NCT02342600: SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor) |
|
|
| Withdrawn | 2 | 0 | NA | Pazopanib, Votrient, Trametinib, Mekinist | Sarcoma Alliance for Research through Collaboration, Novartis | Gastrointestinal Stromal Tumors | 01/20 | | | |
Swecranio, NCT05525273: Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma |
|
|
| Recruiting | 2 | 25 | Europe | Oral dabrafenib and trametinib | Eva Marie Erfurth, MD, PhD, Novartis | Craniopharyngioma | 09/27 | 04/28 | | |